Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists
Supports the body's natural growth hormone production
A yearlong study found that, compared to people using other diabetes drugs, fewer patients who were taking semaglutide sought out medical help to quit smoking
To support safe, effective, and equitable use, there is a clear need for regular, population-level monitoringnot only of the prevalence and patterns of use, but also of access, appropriateness, health outcomes, and broader system impacts